Capstone Investment Advisors Netherlands B.V. trimmed its holdings in Halyard Health, Inc. (NYSE:HYH) by 18.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 5,848 shares of the medical instruments supplier’s stock after selling 1,289 shares during the quarter. Capstone Investment Advisors Netherlands B.V.’s holdings in Halyard Health were worth $230,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of the company. QS Investors LLC raised its holdings in shares of Halyard Health by 305.6% in the second quarter. QS Investors LLC now owns 5,176 shares of the medical instruments supplier’s stock worth $203,000 after buying an additional 3,900 shares during the period. Voya Investment Management LLC raised its holdings in shares of Halyard Health by 81.5% in the second quarter. Voya Investment Management LLC now owns 52,935 shares of the medical instruments supplier’s stock worth $2,079,000 after buying an additional 23,765 shares during the period. Dimensional Fund Advisors LP raised its holdings in shares of Halyard Health by 19.3% in the second quarter. Dimensional Fund Advisors LP now owns 3,133,049 shares of the medical instruments supplier’s stock worth $123,067,000 after buying an additional 507,893 shares during the period. M&T Bank Corp purchased a new stake in shares of Halyard Health in the second quarter worth approximately $404,000. Finally, ETRADE Capital Management LLC raised its holdings in shares of Halyard Health by 4.2% in the second quarter. ETRADE Capital Management LLC now owns 9,671 shares of the medical instruments supplier’s stock worth $380,000 after buying an additional 390 shares during the period. Hedge funds and other institutional investors own 91.02% of the company’s stock.

Several brokerages have recently weighed in on HYH. Stifel Nicolaus reiterated a “buy” rating and issued a $45.00 price target on shares of Halyard Health in a report on Thursday, September 21st. BidaskClub upgraded Halyard Health from a “hold” rating to a “buy” rating in a report on Saturday, August 19th. Deutsche Bank AG increased their price target on Halyard Health from $35.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, August 3rd. Stephens upgraded Halyard Health from an “equal weight” rating to an “overweight” rating in a report on Thursday, August 3rd. Finally, Zacks Investment Research upgraded Halyard Health from a “hold” rating to a “buy” rating and set a $44.00 price target on the stock in a report on Wednesday, July 12th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Halyard Health presently has a consensus rating of “Buy” and a consensus target price of $42.25.

Shares of Halyard Health, Inc. (HYH) traded down 1.27% on Friday, reaching $45.03. The company had a trading volume of 305,778 shares. The stock has a market capitalization of $2.10 billion, a P/E ratio of 43.30 and a beta of 1.76. Halyard Health, Inc. has a 1-year low of $31.59 and a 1-year high of $46.36. The company’s 50 day moving average price is $43.72 and its 200-day moving average price is $39.69.

Halyard Health (NYSE:HYH) last posted its quarterly earnings data on Wednesday, August 2nd. The medical instruments supplier reported $0.51 earnings per share for the quarter, topping analysts’ consensus estimates of $0.37 by $0.14. Halyard Health had a return on equity of 8.29% and a net margin of 3.06%. The business had revenue of $399.20 million for the quarter, compared to analyst estimates of $399.16 million. During the same quarter in the prior year, the company earned $0.45 earnings per share. The company’s revenue was down .2% on a year-over-year basis. Equities analysts predict that Halyard Health, Inc. will post $1.96 EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another site, it was illegally copied and republished in violation of US & international copyright law. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/09/30/halyard-health-inc-hyh-stake-decreased-by-capstone-investment-advisors-netherlands-b-v.html.

Halyard Health Profile

Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.

Institutional Ownership by Quarter for Halyard Health (NYSE:HYH)

Receive News & Stock Ratings for Halyard Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health Inc. and related stocks with our FREE daily email newsletter.